Acquired Factor V Inhibitor Complicated with Immune Thrombocytopenia

Intern Med. 2022 Jan 1;61(1):91-95. doi: 10.2169/internalmedicine.7173-21. Epub 2021 Jun 26.

Abstract

We herein report a patient with a high bleeding tendency as a result of acquired factor V inhibitor and immune thrombocytopenia (ITP). The administration of prednisolone increased the platelet count, but a fatal bleeding event occurred before platelet levels had sufficiently increased. Factor V is stored in not only plasma but also platelets, and platelet-derived factor V might play a local hemostatic role. Bleeding tendency may be high in rare cases where factor V inhibitor is complicated with severe thrombocytopenia. In such patients, physicians should consider aggressive hemostatic therapy, including plasma exchange, in addition to immunosuppressive therapy.

Keywords: acquired factor V inhibitor; fatal hemorrhaging; immune thrombocytopenia; platelet-derived factor V.

Publication types

  • Case Reports

MeSH terms

  • Blood Platelets
  • Factor V
  • Humans
  • Platelet Count
  • Purpura, Thrombocytopenic, Idiopathic* / complications
  • Purpura, Thrombocytopenic, Idiopathic* / diagnosis
  • Purpura, Thrombocytopenic, Idiopathic* / drug therapy
  • Thrombocytopenia* / chemically induced

Substances

  • Factor V